Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29181490 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAHIF1AEPAS1MAPK1 | |
| SCHEMBL3326531 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2GAAHIF1AEPAS1MAPK1 | |
| SCHEMBL11432095 | 0.85 | GAA (0.68) | SMN1; SMN2GAAMAPTALDH1A1CMA1 | |
| SCHEMBL4509396 | 0.82 | ACACB (0.64) | SMN1; SMN2GAAMAPTALDH1A1CMA1 | |
| SCHEMBL3459387 | 0.82 | L3MBTL1 (0.64) | SMN1; SMN2GAAMAPTALDH1A1CMA1 | |
| SCHEMBL23242455 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPK1TSHRMAPTPOLB | |
| SCHEMBL20303832 | 0.81 | L3MBTL1 (0.67) | GAAMAPTALDH1A1CMA1KMT2A | |
| SCHEMBL25081031 | 0.80 | L3MBTL1 (0.61) | SMN1; SMN2GAAMAPK1FKBP1ATSHR | |
| SCHEMBL30996376 | 0.78 | GRM2 (0.60) | SMN1; SMN2GAARAB9ACMA1POLB | |
| SCHEMBL5755331 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAHIF1AEPAS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250179093-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025064542-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2025-02-13 | — | — | US | disclosed |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| CN-112912142-B | 5-Azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-112867715-B | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20210361669-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| CN-112912142-A | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-112867715-A | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3141252-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9518056-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160152614-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-02 | — | — | US | disclosed |
| US-9345708-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140296201-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-8829007-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140142119-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179093-A1 | KRAS MODULATORS | KRAS, NRAS, HRAS | SMN1; SMN2 3622/4885GAA 2015/4885HIF1A 1414/4885 |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | SMN1; SMN2 2585/4885GAA 2385/4885HIF1A 2289/4885 |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | SMN1; SMN2 2585/4885GAA 2385/4885HIF1A 2289/4885 |
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | SMN1; SMN2 4207/4885GAA 2610/4885HIF1A 876/4885 |
| US-20140296201-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | SMN1; SMN2 2932/4885GAA 429/4885HIF1A 1728/4885 |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA1 | SMN1; SMN2 4207/4885GAA 2610/4885HIF1A 876/4885 |
| US-20210361669-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | SMN1; SMN2 4207/4885GAA 2610/4885HIF1A 876/4885 |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | SMN1; SMN2 2585/4885GAA 2385/4885HIF1A 2289/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | SMN1; SMN2 2906/4885GAA 3456/4885HIF1A 2716/4885 |
| US-20160152614-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | SMN1; SMN2 2932/4885GAA 429/4885HIF1A 1728/4885 |
| US-20140142119-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | SMN1; SMN2 2932/4885GAA 429/4885HIF1A 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.